related content
Common call to improve access to medicine
In the run-up to the general debate on Medicines policy on Thursday June 21st 2018, eight organizations in the Netherlands jointly sent a letter to the Dutch Parliament to inform them abouth their position concerning…
Organisations call for greater social impact of the European Commission’s medical research and innovation investments
Together with 22 civil society organisations, SOMO calls on the European Commission to seize the opportunity during the preparation of the 9th Framework Programme The 9th Framework Programme is the follow up of the Horizon…
Roche intimidates clinical drug trial participant following report
Following the publication of a critical report by SOMO on clinical drug trials in Egypt, pharmaceutical company Roche made reprehensible efforts to have damaging information removed from the report. They placed one of the interviewed…
Dialogue and questions in response to report on clinical trials in Egypt
Industry-sponsored clinical drug trials in Egypt
Ethical questions in a challenging context
Embarking on a system change for clinical trials in 2013
In the last few years the pharmaceutical team at SOMO has placed the emphasis on research and lobbying to protect the rights of test subjects in clinical trials. “In 2013 we will continue to be…
Improving protection of test subjects in clinical trials
In recent years, SOMO’s pharmaceutical team has focused on research and lobbying to safeguard the rights of test subjects in clinical trials that take place in low income countries. After the publication of ‘Putting Contract…
Controversial practices in outsourcing of clinical trials
More than half of all clinical trials are outsourced by pharmaceutical companies to subcontractors, the so-called Contract Research Organisations (CROs). As a result quality standards and the independent inspection process are jeopardised, with many negative…
Protection of clinical trial subjects in countries outside the EU
Share this